BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17049064)

  • 1. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients.
    Corcoran TE; Venkataramanan R; Mihelc KM; Marcinkowski AL; Ou J; McCook BM; Weber L; Carey ME; Paterson DL; Pilewski JM; McCurry KR; Husain S
    Am J Transplant; 2006 Nov; 6(11):2765-73. PubMed ID: 17049064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.
    Cicogna CE; White MH; Bernard EM; Ishimura T; Sun M; Tong WP; Armstrong D
    Antimicrob Agents Chemother; 1997 Feb; 41(2):259-61. PubMed ID: 9021176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.
    Husain S; Capitano B; Corcoran T; Studer SM; Crespo M; Johnson B; Pilewski JM; Shutt K; Pakstis DL; Zhang S; Carey ME; Paterson DL; McCurry KR; Venkataramanan R
    Transplantation; 2010 Dec; 90(11):1215-9. PubMed ID: 20881664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
    Palmer SM; Drew RH; Whitehouse JD; Tapson VF; Davis RD; McConnell RR; Kanj SS; Perfect JR
    Transplantation; 2001 Aug; 72(3):545-8. PubMed ID: 11502995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
    Drew RH; Dodds Ashley E; Benjamin DK; Duane Davis R; Palmer SM; Perfect JR
    Transplantation; 2004 Jan; 77(2):232-7. PubMed ID: 14742987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.
    Adedoyin A; Swenson CE; Bolcsak LE; Hellmann A; Radowska D; Horwith G; Janoff AS; Branch RA
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2900-2. PubMed ID: 10991885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.
    Bhamra R; Sa'ad A; Bolcsak LE; Janoff AS; Swenson CE
    Antimicrob Agents Chemother; 1997 May; 41(5):886-92. PubMed ID: 9145839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
    Adedoyin A; Bernardo JF; Swenson CE; Bolsack LE; Horwith G; DeWit S; Kelly E; Klasterksy J; Sculier JP; DeValeriola D; Anaissie E; Lopez-Berestein G; Llanos-Cuentas A; Boyle A; Branch RA
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
    Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
    Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B disposition after aerosol inhalation in lung transplant recipients.
    Marra F; Partovi N; Wasan KM; Kwong EH; Ensom MH; Cassidy SM; Fradet G; Levy RD
    Ann Pharmacother; 2002 Jan; 36(1):46-51. PubMed ID: 11816256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposition of amphotericin B aerosols in pulmonary aspergilloma.
    Diot P; Rivoire B; Le Pape A; Lemarie E; Dire D; Furet Y; Breteau M; Smaldone GC
    Eur Respir J; 1995 Aug; 8(8):1263-8. PubMed ID: 7489788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
    Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
    Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
    Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
    Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
    Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
    Ruijgrok EJ; Vulto AG; Van Etten EW
    J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.